The number of patients within the European Union (EU) deliberately travelling to another EU Member State to receive planned health care is relatively small. People generally prefer to be treated as close to home as possible, with providers speaking their own language, surrounded by relatives and in a system they are familiar with. Patients do, however, prefer to be treated abroad when they are more familiar with the language, culture or health care system across the border or when the appropriate services abroad are nearer than similar services in their country of residence. This is typically the case of citizens living in sparsely populated border regions. Additionally, migrants often prefer to be treated in their countries of origin.
In other circumstances, patients might look for care abroad to escape characteristics and perceived weaknesses in the domestic system, like long waiting lists, types of care that are outlawed (e.g. some fertility treatments) or perceived low quality. When domestic benefit packages cover care only partially or do not cover it at all (for instance dental care or cosmetic surgery), patients might look for cheaper alternatives abroad. 1 Health authorities also can offer patients access to care abroad. Arrangements have been made for care abroad in the case of citizens living in sparsely populated border regions or for highly specialized care in small countries, such as Malta and Luxemburg. 2 Contracting health care abroad can also be an instant, and usually temporary, solution to deal with long waiting lists. 3 A 1971 EU Regulation on the coordination of social security systems established a legal framework under which patients who want to receive planned care in another EU Member State can do so, provided they obtain prior authorization from their domestic purchaser, such as a social insurance fund. 4 Payment is settled between the statutory purchasers of the concerned countries. This system remains in effect today.
Until recently, planned treatment in another EU Member State could be paid for in one of four ways: through this EU Regulation; through cross-border contracts between statutory health purchasers and providers; by the patient; or his or her private health insurer. Since October 2013, a new EU Directive on patients' rights in cross-border healthcare has had to be transposed into national legislation in EU Member States, adding a fifth way to fund care received in other EU Member States to the already existing frameworks. 5 Under the Directive, patients have the right to reimbursement for care up to the level that would be funded for the same treatment at home. Member States can decide to subject elective care to prior authorization when it involves an overnight hospital stay or requires the use of highly specialized and expensive medical facilities and equipment. Authorization may be refused if the treatment can be provided domestically within a time which is medically justifiable.
How important is this new reimbursement right for patients seeking care abroad, and what does it add to the existing frameworks? In two respects, patients might gain an advantage by using the Directive. First, patients obtain new rights to have their care abroad reimbursed for most types of outpatient care without prior authorization from their funding institution. This could meet the needs of patients who perceive that domestic care is of lower quality, that domestic user charges are too high or that care abroad is more familiar. Second, the Directive provides more patient choice as they can, in principle, receive reimbursement for care abroad offered by any provider, whereas under the Regulation on the coordination of social security systems, only providers offering care under the statutory funding system of the country of care provision qualify, and for contracted care, only the contracted providers qualify.
In two regards, the Directive provides no additional benefit for patients. First, patients looking abroad for care that is not covered under the domestic benefit package or that is outlawed at home will not be able to rely on the new Directive to obtain funding, since reimbursement is limited to care that is included in their domestic benefit package.
Second, the Directive can allow patients to escape from domestic waiting lists for inpatient care as well as outpatient care, since prior authorization cannot be refused if the treatment to which the patient is entitled cannot be provided within a medically justifiable time. However, in this respect, the Directive does not provide any additional rights to those guaranteed by the existing Regulation on the coordination of the social security systems, which already provides a similar right to care abroad in case of undue delay at home. 6 In cases in which the patient has the right to choose between the Directive, the Regulation on the coordination of the social security systems, or a cross-border contract, the Directive offers worse opportunities for patients both financially and organizationally. Financially, the Directive is the least beneficial, since the Regulation always guarantees the patient the most beneficial reimbursement tariff, either the one of the country of treatment or the one of the country where the patient is covered for health care. 6 Organizationally, the patient must in principle pay for their treatment abroad up front and only receives reimbursement upon their return home. It is patients who bear the responsibility for ensuring that the care abroad complies with the conditions and criteria of eligibility that apply for care at home and of presenting accurate invoices providing proof of the exact treatment. 7 Patients treated abroad based on the Regulation or cross-border contracts do not have such concerns. Indeed, under the Regulation, they are treated according to the scheme that applies to people covered for health care in the country of treatment, and contracted providers abroad will in principle be paid through the same mechanism through which domestic providers are paid.
In a nutshell, the Directive does improve access to care and patient choice in a relatively limited number of circumstances, in particular for outpatient care. However, the potential burden for patients is substantial and the risk of not being reimbursed is real.
Why then do we have the new reimbursement rules of this Directive, and what is the added value of the new legal framework? The Directive is the result of 15 years searching for policy answers to a series of rulings of the Court of Justice of the EU that applied the fundamental free movement principles of the EU Treaty to health services and products. These principles require the removal of unjustified restrictions on trade between Member States. 8 The Court issued its rulings on a case-by-case basis, which created substantial legal uncertainty. The Directive tries to address these uncertainties and represents a valuable attempt to preserve the governance role of each country's health authorities in the context of the potentially deregulatory dynamic provoked by the free movement principles of the EU Treaty. 9 The Directive may increase legal certainty and transparency on benefit packages, tariffs and reimbursement levels and may push authorities to address weaknesses in the domestic systems, particularly regarding waiting times. It may, however, also require the benefit package to be revised or adapting the payment system. Furthermore, the Directive could be used to further private agendas, in particular to increase consumer choice, to exit the statutory system, to create more competition in the system or to question applicable rules. 10 Paradoxically, such developments could conflict with policies aiming for cost control, which the same EU institutions have insisted on in the context of the current economic and financial crisis.
